QIAGEN

79 articles with QIAGEN

• ATCC Announces Expansion of its Bioinformatics Data Platform with QIAGEN

  4/4/2022

  ATCC, the world’s premier biological materials management and standards organization, announced that it has entered into an agreement with QIAGEN, a recognized leader in bioinformatics solutions, to provide them with sequencing data from its collection of cell lines, and animal and human biological materials.

• Singular Genomics Partners with QIAGEN to Enable QIAseq Kits for the G4 Sequencing Platform

  2/28/2022

  Singular Genomics Systems, Inc. today announced a partnership with QIAGEN to validate its QIAseq kits, a product line for both DNA and RNA sample prep, with the G4 sequencing platform.

• Element Biosciences Partners with QIAGEN to Validate a Selection of QIAseq Targeted Library Construction Chemistries on Element’s AVITI™ System

  2/22/2022

  Element Biosciences, Inc. today announced a partnership with QIAGEN to validate its leading NGS library prep and target enrichment offerings on the AVITI System.

• QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products

  2/8/2022

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2021.

• QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

  12/9/2021

  QIAGEN and Denovo Biopharma LLC announced a collaboration to develop a blood-based companion diagnostic test to identify patients expressing Denovo Genomic Marker 1 who are likely to respond to Denovo’s investigational cancer drug DB102TM for treatment of diffuse large B-cell lymphoma, one of the most common lymphoid cancers.

• Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

  12/9/2021

   Denovo Biopharma LLC and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1™) who are likely to respond to Denovo's investigational cancer drug DB102™ for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.

• QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS

  11/29/2021

  QIAGEN and DiaSorin announced that the U.S. Food and Drug Administration has approved the LIAISON® QuantiFERON®-TB Gold Plus assay for use on DiaSorin’s automated LIAISON® XS platform.

• QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2

  11/2/2021

  QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE-marking of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2.

• QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities

  10/22/2021

  QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchester’s CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.

• QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements

  8/9/2021

  QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab

• QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen

  8/6/2021

  QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its QIAreach® SARS CoV-2 Antigen Test, which is designed for environments that require a high volume of fast and accurate test results.

• QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology

  7/1/2021

  QIAGEN announced a global strategic alliance with Japan’s Sysmex Corporation for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing.

• Statement from Davidson Kempner regarding Qiagen

  6/30/2021

  Qiagen's Supervisory Board suffers from a lack of trust and confidence due to its history of ineffectiveness and governance concerns. This has created a credibility issue that is currently reflected in Qiagen's steep valuation discount to peers and its own historic multiples, and negatively impacts the business.

• 

  QIAGEN Partners with Verogen to Bolster Forensics Field

  6/30/2021

  The two companies will collaborate to market Verogen’s forensically validated NGS workflows alongside QIAGEN’s full range of forensic-grade chemistries and sample prep automation.

• QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments

  6/21/2021

  QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.

• QIAGEN Launches artus Prep as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity

  4/20/2021

  QIAGEN’s innovative technology integrates sample preparation and detection in a single kit, enabling throughput of more than 670 tests per PCR cycler in an eight-hour shift

• Abcam and MEDx extend precision medicine strategic partnership

  4/12/2021

  Abcam, a global innovator in life science reagents and tools, and MEDx Translational Medicine, formerly QIAGEN Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market.

• QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance

  4/6/2021

  QIAseq DIRECT SARS-CoV-2 Kit halves both library preparation times and plasticware use Kit supports analysis of over 6,000 samples simultaneously on highest-throughput sequencers Integrates with QIAGEN Digital Insights cloud solutions to support variant detection and reporting including clade and lineage annotations across sequencing platforms

• QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics

  3/3/2021

  QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.

• QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100 for Advanced Cervical Dysplasia

  2/24/2021

  Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions